{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:51:41Z","timestamp":1789015901672,"version":"build-2803163510"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["C15093BS-Cancer Plan"],"award-info":[{"award-number":["C15093BS-Cancer Plan"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["LABEX TOUCAN"],"award-info":[{"award-number":["LABEX TOUCAN"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","award":["EDYLE"],"award-info":[{"award-number":["EDYLE"]}],"id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["Comites 11,32,65"],"award-info":[{"award-number":["Comites 11,32,65"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>One of the first clinical observations of ibrutinib activity in the treatment of chronic lymphocytic leukemia (CLL) is a rapid decline in lymph nodes size. This phenomenon is accompanied by an hyperlymphocytosis, either transient or prolonged, which is associated with distinct clinical responses and thus has an impact on long-term outcomes. Understanding which factors determine distinct disease courses upon ibrutinib treatment remains a scientific challenge.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>From 2016 to 2021, we conducted a longitudinal and observational study in 2 cohorts of patients with chronic lymphocytic leukemia (CLL) (cohort 1, <jats:italic>n<\/jats:italic> = 41; cohort 2, <jats:italic>n<\/jats:italic> = 81). These cohorts reflect the well-known clinical features of CLL patients, such as Male\/Female sex ratio of 2\/1, a median age of 70 years at diagnosis, and include patients in first-line therapy (27%) or relapsed\/refractory patients (73%). Blood cell counts were followed for each patient during 2 years of ibrutinib treatment. In addition, immunophenotyping and whole-body magnetic resonance imaging (MRI) were assessed in patients from cohort 1. These data were integrated in a newly built mathematical model, inspired by previous mathematical works on CLL treatment and combining dynamical and statistical models, leading to the identification of biological mechanisms associated with the 2 types of clinical responses. This multidisciplinary approach allowed to identify baseline parameters that dictated lymphocytes kinetics upon ibrutinib treatment. Indeed, ibrutinib-induced lymphocytosis defined 2 CLL patient subgroups, transient hyperlymphocytosis (tHL) or prolonged hyperlymphocytosis (pHL), that can be discriminated, before the treatment, by absolute counts of CD4<jats:sup>+<\/jats:sup> T lymphocytes (<jats:italic>p<\/jats:italic> = 0.026) and regulatory CD4 T cells (<jats:italic>p<\/jats:italic> = 0.007), programmed cell death protein 1 PD1 (<jats:italic>p<\/jats:italic> = 0.022) and CD69 (<jats:italic>p<\/jats:italic> = 0.03) expression on B leukemic cells, CD19\/CD5<jats:sup>high<\/jats:sup>\/CXCR4<jats:sup>low<\/jats:sup> level (<jats:italic>p<\/jats:italic> = 0.04), and lymph node cellularity. We also pinpointed that the group of patients identified by the transient hyperlymphocytosis has lower duration response and a poor clinical outcome. The mathematical approach led to the reproduction of patient-specific dynamics and the estimation of associated patient-specific biological parameters, and highlighted that the differences between the 2 groups were mainly due to the production of leukemic B cells in lymph node compartments, and to a lesser extent to T lymphocytes and leukemic B cell egress into bloodstream. Access to additional data, especially longitudinal MRI data, could strengthen the conclusions regarding leukemic B cell dynamics in lymph nodes and the relevance of 2 distinct groups of patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Altogether, our multidisciplinary study provides a better understanding of ibrutinib response and highlights new pharmacodynamic parameters before and along ibrutinib treatment. Since our results highlight a reduced duration response and outcome in patients with transient hyperlymphocytosis, our approach provides support for managing ibrutinib therapy after 3 months of treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Trial registration<\/jats:title>\n<jats:p>ClinicalTrials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT02824159\" xlink:type=\"simple\">NCT02824159<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1004430","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T17:23:21Z","timestamp":1721669001000},"page":"e1004430","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling"],"prefix":"10.1371","volume":"21","author":[{"given":"Sarah","family":"Cadot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0914-2107","authenticated-orcid":true,"given":"Chloe","family":"Audebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Dion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soleakhena","family":"Ken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7278-6503","authenticated-orcid":true,"given":"Loic","family":"Dupr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Largeaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4102-7261","authenticated-orcid":true,"given":"Loic","family":"Ysebaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9979-9638","authenticated-orcid":true,"given":"Fabien","family":"Crauste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1849-6388","authenticated-orcid":true,"given":"Anne","family":"Quillet-Mary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"issue":"8","key":"pmed.1004430.ref001","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41571-018-0037-8","article-title":"Evolution of CLL treatment\u2014from chemoimmunotherapy to targeted and individualized therapy.","volume":"15","author":"JA Burger","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"pmed.1004430.ref002","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib Treatment for First-Line and Relapsed\/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib\/II PCYC-1102 Study","volume":"26","author":"JC Byrd","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"pmed.1004430.ref003","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/1078-0432.CCR-13-0226","article-title":"Molecular Pathways: Targeting the Microenvironment in Chronic Lymphocytic Leukemia\u2014Focus on the B-Cell Receptor","volume":"20","author":"E ten Hacken","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"7","key":"pmed.1004430.ref004","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-15-1965","article-title":"Disruption of in vivo Chronic Lymphocytic Leukemia Tumor\u2013Microenvironment Interactions by Ibrutinib\u2013Findings from an Investigator-Initiated Phase II Study","volume":"22","author":"CU Niemann","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"26","key":"pmed.1004430.ref005","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1182\/blood-2014-02-554220","article-title":"Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib","volume":"123","author":"D Wodarz","year":"2014","journal-title":"Blood"},{"issue":"11","key":"pmed.1004430.ref006","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/leu.2014.122","article-title":"Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study","volume":"28","author":"SEM Herman","year":"2014","journal-title":"Leukemia"},{"key":"pmed.1004430.ref007","first-page":"2","article-title":"Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib","author":"JA Burger","year":"2017","journal-title":"JCI Insight"},{"issue":"4","key":"pmed.1004430.ref008","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1080\/10428194.2018.1512710","article-title":"Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib","volume":"60","author":"JC Barrientos","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"pmed.1004430.ref009","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"JR Brown","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"pmed.1004430.ref010","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"T Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"12","key":"pmed.1004430.ref011","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"AH Lipsky","year":"2015","journal-title":"Haematologica"},{"issue":"26","key":"pmed.1004430.ref012","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"M Levade","year":"2014","journal-title":"Blood"},{"issue":"9","key":"pmed.1004430.ref013","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"JC Riches","year":"2013","journal-title":"Blood"},{"issue":"12","key":"pmed.1004430.ref014","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1080\/10428194.2018.1457147","article-title":"Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia","volume":"59","author":"C Pleyer","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"pmed.1004430.ref015","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"M Long","year":"2017","journal-title":"J Clin Invest"},{"issue":"9","key":"pmed.1004430.ref016","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"JA Fraietta","year":"2016","journal-title":"Blood"},{"key":"pmed.1004430.ref017","first-page":"2832","article-title":"Long-Term Ibrutinib Therapy Reverses CD8+","volume":"10","author":"HM Parry","year":"2019","journal-title":"T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia. Front Immunol"},{"issue":"4","key":"pmed.1004430.ref018","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/leu.2017.304","article-title":"Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1\/PD-L1 pathway","volume":"32","author":"K Kondo","year":"2018","journal-title":"Leukemia"},{"issue":"38","key":"pmed.1004430.ref019","doi-asserted-by":"crossref","first-page":"13906","DOI":"10.1073\/pnas.1409362111","article-title":"Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).","volume":"111","author":"NL Komarova","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"pmed.1004430.ref020","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.leukres.2012.11.015","article-title":"Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia","volume":"37","author":"E Laprevotte","year":"2013","journal-title":"Leuk Res"},{"issue":"1","key":"pmed.1004430.ref021","doi-asserted-by":"crossref","first-page":"015014","DOI":"10.1088\/2057-1976\/abce16","article-title":"Semi-automatic segmentation of whole-body images in longitudinal studies.","volume":"7","author":"E Grossiord","year":"2021","journal-title":"Biomed Phys Eng Express"},{"issue":"21","key":"pmed.1004430.ref022","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1093\/bioinformatics\/btv405","article-title":"Data2Dynamics: a modeling environment tailored to parameter estimation in dynamical systems","volume":"31","author":"A Raue","year":"2015","journal-title":"Bioinformatics"},{"issue":"9","key":"pmed.1004430.ref023","doi-asserted-by":"crossref","first-page":"e74335","DOI":"10.1371\/journal.pone.0074335","article-title":"Lessons Learned from Quantitative Dynamical Modeling in Systems Biology.","volume":"8","author":"A Raue","year":"2013","journal-title":"PLoS ONE"},{"issue":"15","key":"pmed.1004430.ref024","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/bioinformatics\/btp358","article-title":"Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood","volume":"25","author":"A Raue","year":"2009","journal-title":"Bioinformatics"},{"issue":"9790","key":"pmed.1004430.ref025","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(10)61505-X","article-title":"Mathematical models in the evaluation of health programmes","volume":"378","author":"GP Garnett","year":"2011","journal-title":"Lancet"},{"key":"pmed.1004430.ref026","volume-title":"Models, Tasks, Methods and Tools.","author":"M. Lavielle","year":"2014"},{"issue":"1","key":"pmed.1004430.ref027","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1214\/aos\/1018031103","article-title":"Convergence of a stochastic approximation version of the EM algorithm.","volume":"27","author":"B Delyon","year":"1999","journal-title":"Ann Stat."},{"issue":"4","key":"pmed.1004430.ref028","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.csda.2004.07.002","article-title":"Maximum likelihood estimation in nonlinear mixed effects models.","volume":"49","author":"E Kuhn","journal-title":"Comput Stat Data Anal"},{"issue":"9","key":"pmed.1004430.ref029","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1016\/j.jspi.2006.10.013","article-title":"Estimation of parameters in incomplete data models defined by dynamical systems.","volume":"137","author":"A Samson","year":"2007","journal-title":"J Stat Plan Inference"},{"key":"pmed.1004430.ref030","volume-title":"Monolix version 2019R1Antony","year":"2019"},{"issue":"2","key":"pmed.1004430.ref031","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/psp4.12742","article-title":"SAMBA: A novel method for fast automatic model building in nonlinear mixed-effects models.","volume":"11","author":"M Prague","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"pmed.1004430.ref032","article-title":"Rsmlx: R Speaks \u2018Monolix\u2019 [Internet].","author":"M. Lavielle","year":"2021"},{"issue":"7","key":"pmed.1004430.ref033","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1016\/S2352-3026(19)30085-7","article-title":"Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations","volume":"6","author":"JD Soumerai","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"pmed.1004430.ref034","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood-2019-122318","article-title":"Real-World Ibrutinib Validation of the Ball Score to Predict Overall Survival: A Filo Group Study in RR CLL Patients","volume":"134","author":"L Ysebaert","year":"2019","journal-title":"Blood"},{"issue":"5","key":"pmed.1004430.ref035","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/widm.1135","article-title":"On the number of components in a Gaussian mixture model.","volume":"4","author":"GJ McLachlan","year":"2014","journal-title":"WIREs Data Min Knowl."},{"key":"pmed.1004430.ref036","doi-asserted-by":"crossref","DOI":"10.1201\/9781003277965","volume-title":"R. Model-Based Clustering, Classification, and Density Estimation Using mclust in R.","author":"L Scrucca","year":"2023","edition":"1"},{"issue":"1","key":"pmed.1004430.ref037","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ije\/dyh299","article-title":"Regression to the mean: what it is and how to deal with it.","volume":"34","author":"AG Barnett","year":"2004","journal-title":"Int J Epidemiol"},{"issue":"5","key":"pmed.1004430.ref038","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2018-02-830992","article-title":"A CD19\/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era","volume":"132","author":"HR Robinson","year":"2018","journal-title":"Blood"},{"issue":"4","key":"pmed.1004430.ref039","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.","volume":"374","author":"JC Byrd","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"pmed.1004430.ref040","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"M Shadman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"29","key":"pmed.1004430.ref041","doi-asserted-by":"crossref","first-page":"22328","DOI":"10.1074\/jbc.M110.123299","article-title":"CD69 Suppresses Sphingosine 1-Phosophate Receptor-1 (S1P1) Function through Interaction with Membrane Helix 4.","volume":"285","author":"AJ Bankovich","year":"2010","journal-title":"J Biol Chem"},{"issue":"7083","key":"pmed.1004430.ref042","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nature04606","article-title":"CD69 acts downstream of interferon-\u03b1\/\u03b2 to inhibit S1P1 and lymphocyte egress from lymphoid organs","volume":"440","author":"LR Shiow","year":"2006","journal-title":"Nature"},{"issue":"1","key":"pmed.1004430.ref043","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev-immunol-020711-075011","article-title":"Sphingosine-1-Phosphate and Lymphocyte Egress from Lymphoid Organs","volume":"30","author":"JG Cyster","year":"2012","journal-title":"Annu Rev Immunol"},{"issue":"19","key":"pmed.1004430.ref044","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1158\/0008-5472.CAN-15-0986","article-title":"Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia","volume":"75","author":"L Patrussi","year":"2015","journal-title":"Cancer Res"},{"issue":"3","key":"pmed.1004430.ref045","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3324\/haematol.2022.282466","article-title":"Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia","volume":"109","author":"J Rey-Barroso","year":"2023","journal-title":"Haematologica"},{"issue":"22","key":"pmed.1004430.ref046","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/bloodadvances.2019000367","article-title":"Clonal dynamics in chronic lymphocytic leukemia","volume":"3","author":"C Gutierrez","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"pmed.1004430.ref047","doi-asserted-by":"crossref","first-page":"227","DOI":"10.6004\/jnccn.2020.7623","article-title":"Genomic Instability and Clonal Evolution in Chronic Lymphocytic Leukemia: Clinical Relevance.","volume":"19","author":"A Condoluci","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"pmed.1004430.ref048","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/s41467-017-02329-y","article-title":"The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy","volume":"8","author":"DA Landau","year":"2017","journal-title":"Nat Commun"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T17:23:53Z","timestamp":1721669033000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004430"}},"subtitle":[],"editor":[{"given":"Aadel A.","family":"Chaudhuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004430","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]}}}